SINGH SHAWN (CHIEF EXECUTIVE OFFICER) purchased 2287.1% of their position (600K shares) of VISTAGEN THERAPEUTICS, INC. on the open market
Open‑market purchase worth $103.2K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 8/18/2022ACC: 0001415889-22-008814
DirectorOfficer· CHIEF EXECUTIVE OFFICER
Since Aug 2018
+600K
Net shares
Net buyer
$103.2K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
600K acquired
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+600K
Price / share
$0.17
Trade value
$103.20K
% of position
2287.1%
8/17/2022
26.23K→626.23K
Total
Net shares
+600K
Net value
$103.20K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 8/17/2022 | P · Purchase | +600K | $0.17 | $103.20K | 2287.1% | 26.23K | 626.23K |
| Total | +600K | $103.20K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
DirectShares owned154K
Total
154K direct154K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 154K | Direct |
| Total | 154K | 154K direct |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported